Browsing by Author "Kudura, Ken"

Now showing items 1-4 of 4

2023-02-28Zeitschriftenartikel

Additional Primary Tumors Detected Incidentally on FDG PET/CT at Staging in Patients with First Diagnosis of NSCLC: Frequency, Impact on Patient Management and Survival

Kudura, Ken; Ritz, Nando; Templeton, Arnoud; Kissling, Marc; Kutzker, Tim; Foerster, Robert; Hoffmann, Martin H. K.; Antwi, Kwadwo; Kreissl, Michael Christoph

We aimed to assess the frequency of additional primary malignancies detected incidentally on [18F]fluoro-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) at staging in NSCLC patients. Moreover, their ...
2023-11-20Zeitschriftenartikel

An Innovative Non-Linear Prediction Model for Clinical Benefit in Women with Newly Diagnosed Breast Cancer Using Baseline FDG-PET/CT and Clinical Data

Kudura, Ken; Ritz, Nando; Templeton, Arnoud; Kutzker, Tim; Hoffmann, Martin H. K.; Antwi, Kwadwo; Zwahlen, Daniel; Kreissl, Michael Christoph; Foerster, Robert

Objectives: We aimed to develop a novel non-linear statistical model integrating primary tumor features on baseline [18F]-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT), molecular subtype, ...
2021-05-15Zeitschriftenartikel

Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma Patients

Kudura, Ken; Dimitriou, Florentia; Mihic-Probst, Daniela; Muehlematter, Urs J.; Kutzker, Tim; Basler, Lucas; Förster, Robert; Dummer, Reinhard; Mangana, Joanna; Husmann, Lars; Burger, Irene A.; Kreissl, Michael

Background: The use of 18F-2-Fluor-2-desoxy-D-glucose Positron Emission Tomography/Computed Tomography FDG-PET/CT in clinical routine for staging, treatment response monitoring and post treatment surveillance in metastatic ...
2023-05-28Zeitschriftenartikel

Predictive Value of Total Metabolic Tumor Burden Prior to Treatment in NSCLC Patients Treated with Immune Checkpoint Inhibition

Kudura, Ken; Ritz, Nando; Templeton, Arnoud; Kutzker, Tim; Foerster, Robert; Antwi, Kwadwo; Kreissl, Michael Christoph; Hoffmann, Martin H. K.

Objectives: We aimed to assess the predictive value of the total metabolic tumor burden prior to treatment in patients with advanced non-small-cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICIs). Methods: ...